Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

Colleoni, Marco; Bagnardi, Vincenzo; Rotmensz, Nicole; Gelber, Richard D.; Viale, Giuseppe; Pruneri, Giancarlo; Veronesi, Giulia; Torrisi, Rosalba; Cardillo, Anna; Montagna, Emilia; Campagnoli, Elisabetta; Luini, Alberto; Intra, Mattia; Galimberti, Viviana; Scarano, Eloise; Peruzzotti, G.; Goldhirsch, Aron

doi:10.1007/s10549-008-0223-y

Cited by 84 publications

(59 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently we and others showed that the rate of pathological complete remissions (pCR) differs between biologic phenotypes. [1][2][3][4][5] In a smaller subset of the GeparDuo trial [6] patients with a HR+/HER2-had a very low chance of achieving a pCR but had still an excellent prognosis. Whereas patients with HR-/HER2+ tumors have only an excellent prognosis when achieving a pCR.…”

Section: Introductionmentioning

confidence: 99%

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Huober

Minckwitz

Denkert

et al. 2010

Breast Cancer Res Treat

250

146

View full text Add to dashboard Cite

Results: The overall pCR rate, defined as no invasive residuals in breast and axilla, was 20.5 %. The highest pCR rate of 57% was observed in patients below 40 years of age with triple negative or grade 3 tumors. Independent factors for mid-course response and pCR were: young age, non-T4 tumors, high grade, and hormone receptor status, the strongest single predictive factor. Within the biological subtypes grading was an independent factor to predict pCR for luminal tumors, clinical tumor stage for the HER2 like tumors and age for the triple negative ones. Grading gave independent information for mid-course response within the triple negative group. No factor predicted mid-course response within the other groups.Conclusion: Grading and age can identify subgroups within the luminal and triple negative patients who have an increased benefit from neoadjuvant chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Huober

Minckwitz

Denkert

et al. 2010

Breast Cancer Res Treat

250

146

View full text Add to dashboard Cite

show abstract

“…Presurgical chemotherapy, also known as Neoadjuvant or Primary chemotherapy is the current standard of care in these patients. It has been implicated that molecular characteristics of the cancer affect sensitivity to chemotherapy and clinically and pathologically similar tumors may exhibit different response to chemotherapy (Rouzier et al, 2005;Andre and Pusztai 2006;Carey et al, 2007;Colleoni et al, 2009;Coates et al, 2012). The molecular classification of breast cancer therefore provides a new framework for the study of responsiveness to chemotherapy in patients with ABC.…”

Section: Introductionmentioning

confidence: 99%

Association of Immunohistochemically Defined Molecular Subtypes with Clinical Response to Presurgical Chemotherapy in Patients with Advanced Breast Cancer

Khokher¹,

Qureshi²,

Mahmood³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In a recent retrospective analysis of patients treated with preoperative chemotherapy at our Institution, we obtained a 3.3% and 0% pCR rates in patients with incomplete and highly endocrine-responsive tumours, respectively. 24 In the preoperative setting, inconclusive data are available on the association of endocrine therapy with chemotherapy: the combination did not show an improvement of pCR rate in populations unselected for hormone receptor status; however, an effect in proliferative rate decrease in patients with ER-positive tumours has been shown. 25e27 In a trial conducted in our Institution in premenopausal women with endocrine-responsive locally advanced tumours, we observed an increased clinical and pathological response rate by the addition of Gonadotropin Releasing Hormone (GnRH) analogue to chemotherapy as compared to a historical control group treated with chemotherapy alone.…”

mentioning

confidence: 99%

Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer

et al. 2011

Self Cite

View full text Add to dashboard Cite

a b s t r a c tAim: To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer. Patients and Methods: The activity and safety of intravenous pegylated liposomal doxorubicin 20 mg sqm À1 biweekly for eight courses in combination with metronomic cyclophosphamide 50 mg day À1 orally were evaluated in 29 patients with locally advanced breast cancer who were not suitable to receive a standard chemotherapy due to age or co-morbidities or who asked for a regimen with low incidence of toxic effects irrespective of age.Results: The rate of breast-conserving surgery was 44.8%. Eighteen patients (62.1%) achieved a partial response (including one pathological complete response), 10 (34.5%) a stable disease and one patient experienced a progressive disease. Treatment was well tolerated, with no grade 4 toxicities, and with grade 3 skin toxicity in three patients and handefoot syndrome in four patients. Conclusion: The regimen was well tolerated but with limited activity in the preoperative setting. Other options (e.g., endocrine therapy in estrogen receptor -positive disease) should be considered in locally advanced breast cancer patients who are not suitable to receive a standard chemotherapy.

show abstract

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

Cited by 84 publications

References 39 publications

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Association of Immunohistochemically Defined Molecular Subtypes with Clinical Response to Presurgical Chemotherapy in Patients with Advanced Breast Cancer

Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer

Contact Info

Product

Resources

About